

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: AI/ML Innovations Inc. (the "Issuer").

Trading Symbol: AIML

Number of Outstanding Listed Securities: 77,080,197

Date: 1/3/2024

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued to advance its business operations on multiple fronts. Its majority owned subsidiary, Health Gauge, was active in developing additional business relationships and continued development work of its apps and cloud solutions, including custom work for a strategic partner – MedWatch for which Health Gauge is actively involved in the development of MedWatch products and

services. [Note: there is a non-arm's length component to the relationship as the Issuer and MedWatch share a common Officer].

The issuer's minority-owned subsidiary, Tech2Heal, continued business development for its Remote Patient Monitoring Platform (Alakin) and its flagship Qookka mental wellness platform, as well as the implementation of certain feature sets required by potential customers, and readying for several pilot studies.

2. Provide a general overview and discussion of the activities of management.

During the month, management was engaged in business development activities for its various products. It also furthered its discussions with potential channel partners and other potential users of the Health Gauge technology. Consulting work with MedWatch continued by the Health Gauge management towards the advancement of MedWatch's blood glucose monitoring device.

Additionally, management was active in recruiting talent for its Scientific Advisory Board and readying the Health Gauge Neural Net for future FDA approval.

3. Describe and provide details of any new products or services developed or offered.

On February 27, 2024, the Issuer announced that its subsidiary, Health Gauge, reported that it was soon to release "Follow Your Heart", utilizing the Company's proprietary EdgeAI technology, providing a non-invasive blood pressure measurement through the Company's Smart Sensor Watch, that offers users a convenient, effective health & wellness monitoring solution.

4. Describe and provide details of any products or services that were discontinued.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

On February 6, 2024, the Issuer announced it has received the following press release from its majority-owned subsidiary, Health Gauge Inc.:

Health Gauge Inc. announced the launch of a Pilot Program leveraging the newly released Micropayment Platform developed by TODAQ Micro. In collaboration with multiple micropayments participants such as CIBC and Google, Health Gauge Inc. aims to lead the integration of micropayments in healthcare. The inaugural program focuses on utilizing micropayments to access Blood Pressure Measurements through Health Gauge's patented, AI-powered Biometrics Platform.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

See #5 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

On February 27, 2024 the Issuer received the following from its majority-owned subsidiary, Health Gauge Inc.:

After an intensive, three-year journey in research and development, the AI and ML Development team at Health Gauge proudly announces the successful training of their advanced Blood Pressure Measurement Neural Network. This achievement marks a pivotal moment, as the Company will now seek FDA (510(k) Class II) Certification for "Software as a Medical Device". Our proprietary technology is poised to advance healthcare outcomes by providing efficient blood pressure measurements in a consumer wearable smartwatch device while delivering unsurpassed accuracy.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

None.

Security	Number Issued	Details of Issuance	Use of Proceeds

FORM 7 – MONTHLY PROGRESS REPORT

--	--	--	--

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

On February 29, 2024 Bruce Matichuk tendered his resignation as CTO of the Issuer and CTO/Director of Health Gauge. At the same time, Esmat Naikyar accepted the position of interim Chief Product Officer for Health Gauge.

Additionally, February 14, 2024 the Issuer announced the strategic appointment of Dr. David Cramb, Dean of the Faculty of Science at Toronto Metropolitan University, as the Chair of the Company's inaugural Science and Product Advisory Board. This impactful decision reflects AI/ML Innovations Inc.'s unwavering commitment to driving innovation in healthcare through the convergence of artificial intelligence and machine learning with the Company's proprietary and patented technologies.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

There is a growing awareness and acceptance amongst the public, healthcare providers, insurers/payors, and regulators towards the use of digital and virtual healthcare in general, with mental healthcare making up an increasing component of that. This trend is expected to continue at double digit growth rates globally for the next several years. Its acceptance was expedited by the CV-19 pandemic as patients were discouraged from face-to-face medical intervention in all but the most dire of circumstances. The general public has grown to understand the ease and convenience of digital healthcare as a result and healthcare payors understand that the deployment of digital health solutions both improves outcomes and reduces costs. Governments across Europe are implementing laws requiring payors to cover the cost of digital mental health therapy to the same extent as conventional methods.

Additionally, with the recent advancements in artificial intelligence and the general public's awareness of same, investors and strategic partners are showing a keen and growing interest in sourcing investments in the AI space. Predictions show that AI will have a multi trillion-dollar impact on the global economies and effect almost all facets of modern society. As this is the core business of the Issuer, we expect to benefit positively and significantly, both in terms of investor awareness as well as business development opportunities from this generational event.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated 1/03/2024

Tim Daniels

Name of Director or Senior
Officer

/S/ "Tim Daniels"

Signature

Executive Chairman

Official Capacity

Issuer Details Name of Issuer AI/ML Innovations Inc.	For Month End February 2024	Date of Report YY/MM/D 24/03/01
Issuer Address Suite 203, 645 Fort St.		
City/Province/Postal Code Victoria, BC V8W 1G2	Issuer Fax No.	Issuer Telephone No. (778) 405-0882
Contact Name Tim Daniels	Contact Position Director	Contact Telephone No. 250 483-5650
Contact Email Address tim.daniels@aiml-innovations.com	Web Site Address aiml-innovations.com	